Stocks and Investing Stocks and Investing
Mon, January 10, 2022
Sun, January 9, 2022
Fri, January 7, 2022
Thu, January 6, 2022

Matthew Harrison Downgraded (AVIR) to Sell and Decreased Target to $7 on, Jan 6th, 2022


Published on 2024-10-27 19:09:39 - WOPRAI, Matthew Harrison
  Print publication without navigation


Matthew Harrison of Morgan Stanley, Downgraded "Atea Pharmaceuticals, Inc." (AVIR) to Sell and Decreased Target from $14 to $7 on, Jan 6th, 2022.

Matthew has made no other calls on AVIR in the last 4 months.



There are 2 other peers that have a rating on AVIR. Out of the 2 peers that are also analyzing AVIR, all agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Roanna Ruiz of "SVB Leerink" Downgraded from Buy to Hold and Held Target at $11 on, Thursday, November 18th, 2021
  • Eric Joseph of "JP Morgan" Downgraded from Buy to Hold and Decreased Target to $16 on, Wednesday, October 20th, 2021